Objective:To evaluate and compare the effects and safety of the oxytocin receptor inhibitors and β-receptor agonist in the treatment of premature delivery. Methods:Based on searching the related literatures from the database by computer,we do a comprehensive collection of randomized trial comparing treatments on the oxytocin receptor inhibitor Atosiban and β receptor agonists including Ritodrine,Salbutamol,Terbutaline. Besides,we do Meta-analysis to the clinical research meeting the inclusive criteria,then we use Cochrane Collaboration RevMan 5.0 software for data processing. Results:A total of six literatures has been identified,Atosiban andβ-receptor agonist in the extended gestation of 48 h (RR=1.00,95%CI:0.97-1.04,P=0.90),7 d (RR=1.04,95%CI:0.99-1.09,P=0.14),the difference of the above two groups was not statistically significant;There was no significant difference between the Atosiban group and β-receptor agonist group in gestational age at birth (WMD=0.18,95%CI:-0.19-0.55,P=0.34) and the average weight at birth (WMD=-33.89,95%CI:-108.57-40.79,P=0.37). However,as to tolerability and efficacy,un-delivery within the 48h and requiring no other tocolytic agent (RR=1.07,95%CI:1.01-1.14,P=0.03) and un-delivery within 7 d and needing no other miscarriage drugs (RR=1.25,95%CI:1.14-1.37,P<0.05) difference of the Atosiban group andβ-receptor agonist group was statistically significant;and incidence of side effects in the mother,especially tachycardia has significant difference (RR=0.09,95%CI:0.05-0.17,P<0.000 01);differences in the number of discontinuation people due to side effects of maternal between the Atosiban group and β-agonist group was significant (RR=0.08,95%CI:0.05-0.14,P<0.000 01). Conclusions:Compared with β-agonist,Atosiban can achieve the similar therapeutic effect in the treatment of premature delivery,however,its tolerance is much stronger than theβ-agonist and incidence of side effects in maternal is much less.%目的：评价缩宫素受体拮抗剂和β受体激动剂治疗妊娠妇女早产的效果和安全性。方法：计算机检索相关数据库，全面收集缩宫素受体拮抗剂阿托西班与β受体激动剂（包括利托君，沙丁胺醇，沙布他林）比较治疗早产的随机临床试验，对符合纳入标准的临床研究进行Meta分析，应用Cochrane协作网提供的Revman 5.0软件进行数据处理。结果：共纳入6篇文献，2组阿托西班和β受体激动剂延长孕周48 h人数（RR=1.00，95%CI为0.97～1.04， P=0.90）和孕周7 d人数（RR=1.04，95%CI为0.99～1.09，P=0.14）的差异无统计学意义；2组新生儿出生胎龄（WMD=0.18，95%CI为-0.19～0.55，P=0.34）和出生时平均体质量（WMD=-33.89，95%CI为-108.57～40.79，P=0.37）差异也无统计学意义。但在耐受性及效力上，即48 h内（RR=1.07，95%CI为1.01～1.14，P=0.03）及7 d内（RR=1.25，95%CI为1.14～1.37，P＜0.05）未分娩且不需其他保胎药差异有统计学意义；在母体不良反应尤其是心动过速发生率上差异有统计学意义（RR=0.09，95%CI为0.05～0.17，P＜0.00001）；2组因母体发生不良反应而停药的人数差异也有统计学意义（RR=0.08，95%CI为0.05～0.14，P＜0.00001）。结论：阿托西班在治疗早产方面可以达到β受体激动剂相似的治疗效果，但是在耐受性上比β受体激动剂强，且母体不良反应发生率较少。
展开▼
